EVROPSKÁ HEMATOLOGICKÁ ASOCIACE 23. KONGRES, STOCKHOLM
Jaroslav Čermák |
|
ANÉMIE – DIAGNOSTIKA A LÉČBA PORUCH ČERVENÉ KREVNÍ ŘADY
Jaroslav Čermák |
|
IMPROVEMENTS IN HEMOGLOBIN, QUALITY OF LIFE, AND SIX-MINUTE-WALK DISTANCE IN ADULTS WITH β-THALASSEMIA TREATED WITH LUSPATERCEPT: LONG-TERM PHASE 2 STUDY
Antonio Piga, Immacolata Tartaglione, Maria Rita Gamberini, Ersi Voskaridou, et al. |
|
HEPCIDIN MIMETIC PTG-300 FOR TREATMENT OF INEFFECTIVE ERYTHROPOIESIS AND CHRONIC ANEMIA IN HEMOGLOBINOPATHY DISEASES
Greg Bourne, Li Zhao, Ashok Bhandari, Brian Frederick, et al. |
|
ACTIVATE: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AG-348 IN ADULTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
Marie-Hélène Jouvin, Chris Bowden |
|
Aktuálne otázky liečby primárnej imunitnej trombocytopénie
Angelika Bátorová |
|
PERIOPERATIVE USE OF ELTROMBOPAG IN PATIENTS WITH CHRONIC THROMBOCYTOPENIA. A SINGLE-CENTER EXPERIENCE
Elena Landete, Amalia Domingo, Gloria Pérez-Rus, et. al. |
|
FINAL SAFETY AND EFFICACY DATA OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)
Michael Tarantino, James Bussel, Victor Blanchette, et. al. |
|
ELTROMBOPAG TREATMENT IN PATIENTS WITH PERSISTENT VERSUS CHRONIC IMMUNE THROMBOCYTOPENIA: COMPARISON OF EFFICACY AND SAFETY RESULTS FROM THE PHASE III EXTEND STUDY AND A PHASE IV STUDY
Raymond SM Wong, Oliver Meyer, Tahir Shamsi, et. al. |
|
FACTORS AFFECTING THROMBOPOIETIN RECEPTOR AGONIST REINITIATION AFTER DISCONTINUATION IN WELL-CONTROLLED PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN THE UK: RESULTS FROM A MODIFIED DELPHI CONSENSUS PANEL
Nichola Cooper, Quentin Hill, John Grainger, et. al. |
|
COMPARISON OF STANDARD- AND LOW-DOSE RITUXIMAB IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): DATA FROM THE UK ITP REGISTRY
Caitlin Gracie, Abbas Zaidi, Umesh Doobaree, et. al. |
|
LONG-TERM SAFETY AND EFFICACY OF RITUXIMAB IN 248 ADULT IMMUNE THROMBOCYTOPENIA PATIENTS: RESULTS WITH MORE THAN 5 YEARS OF FOLLOW-UP FROM A FRENCH PROSPECTIVE REGISTRY ITP-RITUX
Samuel Deshayes, Mehdi Khellaf, Anissa Zarour, et. al. |
|
AKUTNÍ MYELOIDNÍ LEUKEMIE – NOVINKY V DIAGNOSTICE A LÉČBĚ
Tomáš Stopka |
|
RESULTS OF PIVOTAL PHASE 2 TRIAL OF SL-401 IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
Naveen Pemmaraju, Kendra Sweet, Andrew Lane, Anthony Stein, et al. |
|
ARRAYED MOLECULAR BARCODING IDENTIFIES TNFSF13 AS A POSITIVE REGULATOR OF ACUTE MYELOID LEUKEMIA-INITIATING CELLS
Marion Chapellier, Pablo Peña-Martínez, Ramprasad Ramakrishnan, Mia Eriksson, et al. |
|
RESULTS FROM 48-WEEK FOLLOW-UP OF THE EXPAND STUDY: A PHASE 1B, OPEN-LABEL, DOSE-FINDING STUDY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND LOW PLATELET COUNTS (50-99 × 109/L) AT BASELINE
Alessandro M. Vannucchi, Peter te Boekhorst, Claire N. Harrison, Guangsheng He, Marianna Caramella, Dietger Niederwieser, Françoise Boyer-Perrard, Minghui Duan, Nathalie Francillard, Betty Molloy, Monika Wroclawska, Heinz Gisslinger |
|
Nedostatok vitamínu D a znížené prežívanie pacientov s Hodgkinovým lymfómom
Ľuboš Drgoňa |
|
PRETREATMENT VITAMIN D DEFICIENCY IS ASSOCIATED WITH LOWER PROGRESSION- -FREE AND OVERALL SURVIVAL IN PROSPECTIVELY TREATED HODGKIN LYMPHOMA
Sven Borchmann, Helen Görgen, Stephanie Sasse, et. al. |
|
FINAL ANALYSIS OF THE AHL201 RANDOMIZED PHASE III LYSA STUDY COMPARING AN EARLY PET DRIVEN TREATMENT DE-ESCALATION TO A NOT PET-MONITORED STRATEGY IN PATIENTS WITH ADVANCED STAGES HODGKIN LYMPHOMA
Olivier Casasnovas, Pauline Brice, Reda Bouabdallah, et. al |
|
ADDING POLATUZUMAB VEDOTIN (POLA) TO BENDAMUSTINE AND RITUXIMAB (BR) TREATMENT IMPROVES SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: RESULTS OF A PHASE 2 CLINICAL TRIAL
Laurie H. Sehn, Manali Kamdar, Alex F. Herrera, et. al. |
|
RELEVANCE: PHASE III EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY, FOLLOWED BY RITUXIMAB, IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
Frank Morschhauser, Nathan H. Fowler, Pierre Feugier, et. al |
|
AN UPDATED ANALYSIS OF JULIET, A GLOBAL PIVOTAL PHASE 2 TRIAL OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Peter Borchmann, Constantine S. Tam, Ulrich Jäger |
|
AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES BY PRIOR LINES OF THERAPY IN ZUMA-1
Frederick L. Locke, Armin Ghobadi, Lazaros J. Lekakis, et. al. |
|
MYELODYSPLASTICKÝ SYNDROM – VÝBĚR Z EDUKAČNÍCH SDĚLENÍ A POSTERŮ
Libor Červinek |
|
SEVERE THROMBOCYTOPENIA AS A PREDICTOR OF SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS: DATA FROM A LATIN-AMERICAN COHORT
Carolina Lazzarino, Marcelo Iastrebner, Jacqueline Gonzalez, Jorge Arbelbide, et al. |
|
DESCRIPTION OF MUTATIONAL PROFILE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES AT THE TIME OF LEUKEMIC PROGRESSION
Begoña Pedrote, Jose Francisco Falantes, Estrella Carrillo, Cristina Calderon-Cabrera, et al. |
|
INTENSIVE CHEMOTHERAPY (IC) IS MORE EFFECTIVE THAN HYPOMETHYLATING AGENTS (HMA) FOR THE TREATMENT OF YOUNGER PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ELEVATED BONE MARROW BLASTS
Paolo Strati, Guillermo Garcia-Manero, Tapan Kadia, Gautam Borthakur, et al. |
|
PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND MULTILINEAGE DYSPLASIA WITH OR WITHOUT RING SIDEROBLASTS
Abhishek Mangaonkar, Terra Lasho, Christy Finke, Naseema Gangat, et al. |
|
MNOHOPOČETNÝ MYELÓM - Novinky z kongresu
Ľubica Harvanová |
|
A TRIPLET BORTEZOMIB- AND IMMUNOMODULATOR-BASED THERAPY BEFORE AND AFTER DOUBLE ASCT IMPROVES OVERALL SURVIVAL OF NEWLY DIAGNOSED MM PATIENTS: FINAL ANALYSIS OF PHASE 3 GIMEMA-MMY-3006 STUDY
Paola Tacchetti, Francesca Patriarca, Maria Teresa Petrucci, et. al. |
|
CONSOLIDATION FOLLOWED BY MAINTENANCE VS MAINTENANCE ALONE IN NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE MULTIPLE MYELOMA: A RANDOMIZED PHASE 3 STUDY OF THE EUROPEAN MYELOMA NETWORK (EMN02/HO95 MM TRIAL)
P Sonneveld, M Beksac, B vanderHolt, et. al. |
|
LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS
Francesca Gay, Lorenzo De Paoli, Alessandra Larocca |
|
BUSULFAN + MELPHALAN WAS ASSOCIATED WITH A LONGER PFS COMPARED TO MELPHALAN ALONE IN HIGH-RISK MULTIPLE MYELOMA IN A RANDOMIZED PHASE 3 CLINICAL TRIAL
Muzaffar Qazilbash, Qaiser Bashir, Peter Thall, et. al. |
|
ONCE-WEEKLY VS TWICE-WEEKLY CARFILZOMIB DOSING PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE RANDOMIZED PHASE 3 STUDY A.R.R.O.W.
Maria-Victoria Mateos, Philippe Moreau, James R. Berenson, et. al. |
|
ZPRÁVA ZE SYMPOZIA SPOTLIGHT ON PRECISION MEDICINE IN MYELOID MALIGNANCIES
Ladislav Fekete |
|
